Objective To reduce the relapse rate for hematological malignancies after allogeneic hematopoietic stem cell transplantation, we employed a myeloablative regimen comprising thiotepa 400 mg/m 2 , cyclophosphamide 3,600 mg/m 2 and total body irradiation 10 Gy. Subjects comprised 17 patients (median age, 53 years; range,[50][51][52][53][54][55][56] with hematological malignancies who received allogeneic hematopoietic stem cell transplantation from HLAidentical related (n=6), HLA-mismatched family (n=2) or unrelated donors (n=9). Prophylaxis of acute graftversus-host disease (GVHD) consisted of short-term methotrexate and cyclosporine (n=4) or short-term methotrexate and tacrolimus (n=13). Results No grade IV regimen-related toxicities as determined by Bearman's criteria were encountered. Acute grade II-IV GVHD developed in 7 patients, with chronic GVHD in 11 patients. With a median followup of 39 months, 3 years survival rate after transplantation was 59%. Two patients died due to infection by 100 days after transplantation. Only 1 patient with Philadelphia-positive acute lymphoblastic leukemia experienced relapse. Eight patients died of non-leukemic causes (sepsis, n=2; liver dysfunction, n=2; idiopathic interstitial pneumonia, n=1; bacterial pneumonia, n=1; bronchiolitis obliterans resulting from chronic GVHD, n=1; and disseminated infection with varicella zoster virus, n=1). Conclusions This regimen was tolerable, but a large trial is warranted to confirm the efficacy of this conditioning.
Introduction
Advanced age is associated with a poor prognosis following allogeneic hematopoietic stem cell transplantation (HSCT) because of medical complications such as hypertension and diabetes mellitus, increased toxicity of conditioning regimens and high incidence of graft-versus-host disease (GVHD) (1, 2) . Although non-myeloablative transplantation allows older patients to become transplant candidates, the high incidence of relapse of hematological malignant disease after transplantation remains an obstacle, particularly for patients with high-risk disease (3) (4) (5) (6) .
Thiotepa (TT) is a cell cycle-independent alkylating agent with limited extramedullary toxicity (7) . We have previously shown that addition of TT to cyclophosphamide (CY) and total body irradiation (TBI) reduces the relapse rate without increasing the rate of treatment-related mortality for patients T a b l e 1 . P a t i e n t Ch a r a c t e r i s t i c s with myelodysplastic syndrome (8) . The present study applied this conditioning regimen while reducing doses of CY and TBI by about 20% for patients !50-years-old with hematological malignant disease. Table 1 .
Materials and Methods

Patients
Subjects comprised 17 patients with hematological malignancies who received allogeneic HSCT between April 1999 and March 2004. Patient characteristics are listed in
Transplant modalities
The conditioning regimen comprised intravenous TT at 200 mg/m 2 /day for 2 consecutive days (total, 400 mg/m 2 ), intravenous CY at 1,800 mg/m 2 /day for 2 consecutive days (total, 3,600 mg/m 2 ) and TBI (10 Gy in 4 fractions). The combination chemotherapy was administered either before (10 cases) or after (7 cases) TBI. Regimen-related toxicities (RRTs) were graded using the system previously described by Bearman et al (9) .
Transplant from an HLA-identical sibling donor was used for 6 patients. Of these, 4 patients received bone marrow and 2 patients received peripheral blood stem cells (PBSC). Transplant with HLA-one locus mismatched family bone marrow was used for 2 patients. Transplant from HLAserological identical unrelated bone marrow was used for 8 patients. Transplant with HLA-one locus mismatched unre-lated bone marrow was used for 1 patient. Bone marrow was harvested by standard technique using general anesthesia with a target yield of !2×10 8 nucleated cells per kilogram of recipient weight. PBSC donors were treated with 10 μg/kg of G-CSF subcutaneously for 4-5 days and leukopheresis with a target yield of !2×10 6 CD34 + cells per kilogram of recipient weight was performed for 1 or 2 days.
Prophylaxis against acute GVHD comprised short-term methotrexate (MTX) and cyclosporine (n=4) or short-term MTX and tacrolimus (n=13). MTX was administered intravenously at a dose of 10 mg/m 2 on day 1 and 7 mg/m 2 on days 3 and 6. Starting dose of cyclosporine (3 mg/kg/day) or tacrolimus (0.03 mg/kg/day) was administered by continuous intravenous infusion from day -1. These doses were modified to maintain whole blood levels of 270-300 ng/ml for cyclosporine and 15-20 ng/ml for tacrolimus. Cyclosporine or tacrolimus was tapered from day 50 in patients without evidence of GVHD and discontinued on day 150-180. If grade II-IV acute GVHD developed, patients were treated with prednisolone in doses of 1-2 mg/kg/day. Patients with extensive chronic GVHD were treated using prednisolone and cyclosporine or tacrolimus. Both acute and chronic GVHD were graded according to previously published criteria (10, 11) . All patients were isolated in a laminar air-flow room and administered antibiotics and antifungal agents for gastrointestinal decontamination until engraftment. Lenograstim (5 μg/kg/day) was given by intravenous infusion over 24 hours starting on day 1, and continued until engraftment. Engraftment was defined by a neutrophil T a b l e 2 . Re g i me n -r e l a t e d T o x i c i t i e s
F i g u r e 1 . Ka p l a n -Me i e r e s t i ma t e s o f t h e p r o b a b i l i t y o f o v e r a l l s u r v i v a l f o r a l l p a t i e n t s . S e v e n t e e n p a t i e n t s a g e d 5 0 y e a r s a n d o v e r r e c e i v e d a l l o g e n e i c h e ma t o p o i e t i c t r a n s p l a n t at i o n f o l l o wi n g t h e c o n d i t i o n i n g r e g i me n c o mp r i s i n g t h i o t e p a , c y c l o p h o s p h a mi d e , a n d t o t a l b o d y i r r a d i a t i o n .
count of !0.5×10 9 /l.
Results
Engraftment was achieved at a median of 18 days (range, 13-32 days), and a platelet count of 20×10 9 /l was reached at a median of 27 days (range, 16-142 days) in 16 patients. One patient with high-risk disease died of sepsis on day 9 before achieving engraftment.
RRTs are shown in Table 2 . Stomatitis was observed in all patients. No grade IV RRTs was found in 16 of the 17 patients analyzed, except for one patient who died of sepsis on day 9. Acute grade II-IV GVHD developed in 7 patients, including grade III in 3 patients and grade IV in 1 patient. Extensive chronic GVHD occurred in 7 patients, while limited chronic GVHD was seen in 4 patients.
Median follow-up time for the surviving patients was 39 months (range, 30-81 months). As of final follow-up, 8 of 17 patients remained alive without relapse. The estimated probability of 3 years survival was 59% for all patients (Fig. 1) . One patient with Philadelphia-positive acute lymphoblastic leukemia experienced relapse. The estimated probability of 3 years survival was 64% for 14 patients with AML or MDS. The estimated probability of 3 years survival was 75% for 4 patients with standard-risk disease, while 54% for 13 patients with high-risk disease (p=0.12). Eight patients died of non-leukemic causes, comprising: sepsis (n= 2); hepatic veno-occulusive disease (n=1); fulminant hepatitis due to reactivation of hepatitis B virus (n=1); idiopathic interstitial pneumonia (n=1); bacterial pneumonia (n=1); bronchiolitis obliterans resulting from chronic GVHD (n=1); and disseminated infection of varicella zoster virus (n=1) ( Table 3) . Cumulative incidence of non-relapse death within 100 days was 12%. (13, 14) . These results suggest that the intensity of the conditioning regimen is important in cases of hematological malignant disease, especially highrisk disease.
Discussion
Allogeneic HSCT has been used to effectively treat a variety of hematological malignancies. Several reports have demonstrated the feasibility of non-myeloablative transplantation in older patients (4-6). Although non-myeloablative transplantation reduces transplant-related mortality, the high relapse rate has been problematic. Alyea et al (12) compared outcomes between non-myeloablative and myeloablative transplantation for patients >50 years old. Although the nonrelapse mortality rate was lower for non-myeloablative transplantation, the relapse rate was higher. The success of allogeneic HSCT in eradicating malignant hematological disorders depends on the following factors: 1) ability of the conditioning regimen to reduce or eliminate clonogeneic malignant cells; and 2) occurrence of a graft-versus-tumor effect mediated by donor lymphocytes. Donor lymphocyte infusion is not particularly effective except for chronic-phase chronic myelogenous leukemia
TT is characterized by an initial, rapid diffusion-mediated uptake into tumor cells followed by irreversible binding to intracellular macromolecules (15) (16) (17) . The two major doselimiting toxicities of TT are expressed in the central nervous system and gastrointestinal tract (18). These adverse effects are relatively specific for the high-dose setting and must be considered when TT is given in combination with other drugs that have the potential to produce overlapping extramedullary toxicities. TT has been safely added to the CY/ TBI regimen for patients with acute myelogenous leukemia or acute lymphoblastic leukemia (7, 19) . TT is lacks overlapping dose-limiting toxicities with CY (18). In the present study, the regimen comprising TT with 20%-reduced CY T a b l e 3 . Ou t c o me s o f T r a n s p l a n t a t i o n and TBI in patients !50 years old also did not lead to increased incidence or severity of RRTs. The relatively low dose of TT (200 mg/m 2 /day) in our study might contribute to acceptable RRTs. Bieri et al (20) showed that higher TBI doses are deleterious for older patients with three different fractionated TBI regimens up to total doses of 10, 12 and 13.5 Gy. They showed better survival with 10 Gy of TBI. In the present study, use of 10 Gy of TBI might have contributed to the low incidence of RRTs. McDonald et al (21) showed that metabolism of CY is variable between patients, with increased exposure to toxic metabolites of CY leading to increased liver toxicity. Although we did not measure toxic metabolites of CY, reduction in the CY dose might have contributed to the low incidence of RRTs.
We showed 3 years overall survival rates of 59% in patients, including 76% with high-risk disease. Excluding 1 patient with Philadelphia-positive acute lymphoblastic leukemia, the 8 survivors did not experience relapse. As the sample size was small, no correlation was identified between GVHD and relapse. Although the results were obtained in a small number of patients, this regimen appears effective for preventing relapse. But death of non-leukemic causes after engraftment was a problem; 5 patients died with infection. As immune reconstitution of patients aged 50 years and over is delayed (22) , more critical supportive care for infections might be needed to decrease death of non-leukemic causes.
In conclusion, a regimen comprising TT with 20%- 
